A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

This is an open-label, single-arm, Phase 2 study of pembrolizumab plus platinum and gemcitabine (PG) in subjects with recurrent or metastatic head and neck cancer squamous cell carcinoma (R/M HNSCC). Evaluable 63 subjects with R/M HNSCC will be enrolled for examination of the efficacy and safety of the combination of pembrolizumab (200 mg IV on Day 1 of each 3-week cycle, up to 35 cycles) in combination with platinum (either cisplatin at 35 mg/m2 IV using a split-dose regimen on Day 1 and Day 8 or carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles) and gemcitabine at 1250 mg/m2 IV on Day 1 and 8 of each 3-week cycle, for up to 6 cycles as first-line treatment. This study will be conducted in conformance with Good Clinical Practices. Specific procedures to be performed during the trial, as well as their prescribed timelines and associated visit windows, are outlined in the protocol.

NCT Number	NCT05286619
Lead Sponsor	University of Malaya Collaborators: Cancer Research Malaysia, Kuala Lumpur General Hospital, National Cancer Institute, Malaysia, Merck Sharp & Dohme LLC, My Starfish Foundation, Yayasan Sime Darby, Yayasan PETRONAS
Conditions	Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment	63 participants
Start Date	2022-09-22
Primary Completion	2025-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2024-10-15